2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1362

Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Abstract Number: 1363

Serum Adipokines in Juvenile Dermatomyositis Are Associated with Disease Activities and Cardiac Function
Abstract Number: 1364

Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
Abstract Number: 1365

Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Abstract Number: 1366

Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Abstract Number: 1367

Long-Term Outcomes and Their Predictors in Patients with Juvenile Idiopathic Inflammatory Myopathies of Adult Age: A Referral Population Study
Abstract Number: 1368

Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Abstract Number: 1369

Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Abstract Number: 1370

Development and Validation of a Composite Disease Activity Score for Juvenile Dermatomyositis
Abstract Number: 1371

Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis
Abstract Number: 1372

Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis
Abstract Number: 1373

Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Abstract Number: 1374

Predictors of Changes in Disease Activity Among Children with Juvenile Dermatomyositis
Abstract Number: 1375

A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes
Abstract Number: 1376

In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].